טוען...
Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
Famitinib (SHR1020), a novel multi-targeted tyrosine kinase inhibitor, has antitumor activity against several solid tumors via targeting vascular endothelial growth factor receptor 2, c-Kit and platelet-derived growth factor receptor β. The present study investigated famitinib's activity agains...
שמור ב:
| הוצא לאור ב: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
D.A. Spandidos
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998225/ https://ncbi.nlm.nih.gov/pubmed/27602110 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.4909 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|